Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

NCT06093061 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

COMBINATION_PRODUCT: CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

Sponsor

National Cancer Centre, Singapore

Collaborators

[object Object]
[object Object]